bone marrow transplants
DURHAM, N.C. -- Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.
Flies fed an "anti-Atkins" low protein diet live longer because their mitochondria function better. The research, done at the Buck Institute for Age Research, shows that the molecular mechanisms responsible for the lifespan extension in the flies have important implications for human aging and diseases such as obesity, diabetes and cancer.
Pediatric researchers have resolved an apparent contradiction in the field of prenatal cell transplantation -- a medical approach that holds future promise in correcting sickle cell disease and other serious congenital blood disorders.
Research on blood transfusions points to a potential risk of transfusing donated platelets, especially to patients with bone marrow failure syndromes who are subsequently candidates for bone marrow transplantation.
The results are online and scheduled for publication in the September 1 issue of the Journal of Clinical Investigation.
MADISON -- In an advance that could help transform embryonic stem cells into a multipurpose medical tool, scientists at the University of Wisconsin-Madison have transformed these versatile cells into progenitors of white blood cells and into six types of mature white blood and immune cells.
ANN ARBOR, Mich. -- University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.
Two new studies reveal a way to increase the body's appetite for gobbling up the cancer stem cells responsible for acute myeloid leukemia (AML), a form of cancer with a particularly poor survival rate.
Tampa, FL (July 1, 2009) -- A human growth factor that stimulates blood stem cells to proliferate in the bone marrow reverses memory impairment in mice genetically altered to develop Alzheimer's disease, researchers at the University of South Florida and James A. Haley Hospital found.
A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine.
University of Toronto researchers have discovered an ample source of stem cells in an uncharted part of the umbilical cord, providing new hope for bone marrow transplants and tissue repair. The study, published in the February issue of Stem Cells, outlines how researchers discovered that the jelly-like connective tissue surrounding the blood vessels of the human umbilical cord, the so-called "Wharton's Jelly," is rich in mesenchymal progenitor cells – cells that generate bone, cartilage and other tissues – and can be harvested to generate an abundant supply in a short amount of time. This expandable source of progenitor cells could greatly improve bone marrow transplantation, a painful yet common procedure that currently has a 30 to 40 per cent success rate in treating disease.
Scientists have finally laid hands on the first member of a recalcitrant group of proteins called the Wnts two decades after their discovery. Important regulators of animal development, these proteins were suspected to have a role in keeping stem cells in their youthful, undifferentiated state - a suspicion that has proven correct, according to research carried out in two laboratories at Stanford University Medical Center. The ability to isolate Wnt proteins could help researchers grow some types of stem cells for use in bone marrow transplants or other therapies.
An international team of researchers has used a gene test to identify certain patients with adult T-cell acute lymphoblastic leukemia (ALL) who can be successfully treated with chemotherapy alone and should not be subjected to the rigors of bone marrow transplants. The researchers found that these patients survived for at least three years after being treated with intensive chemotherapy. It was previously known that only slightly over half of the patients with this disease could be cured with chemotherapy. Adult ALL patients often undergo transplants in an effort to beat back the stubborn disease. Until now there was no way to identify those who have a more favorable outlook and shouldn't undergo risky bone marrow transplantation.
